Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI
Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance. The platelet aggregation rate with arachidonic acid (AA, PAg-AA%) and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-03-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296221083674 |
| _version_ | 1818138487895883776 |
|---|---|
| author | Lijie Zhang PhD, MD Ying Lv PhD, MD Jianyu Dong PhD, MD Nana Wang MSc Zhan Zhan MSc Yuan Zhao BSc Shanshan Jiang PhD, MD |
| author_facet | Lijie Zhang PhD, MD Ying Lv PhD, MD Jianyu Dong PhD, MD Nana Wang MSc Zhan Zhan MSc Yuan Zhao BSc Shanshan Jiang PhD, MD |
| author_sort | Lijie Zhang PhD, MD |
| collection | DOAJ |
| description | Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance. The platelet aggregation rate with arachidonic acid (AA, PAg-AA%) and adenosine diphosphate (ADP, PAg-ADP%) of 219 PCI patients were measured after standard treatment for 24 h. The disease history and laboratory data (before PCI) were obtained. We found 101 (46.12%) patients to be aspirin-resistant, and PAg-ADP% was the most prominent risk factor of aspirin resistance. Clopidogrel resistance was present in 157 of 219 patients. Patients in the clopidogrel-resistant group carried more CYP2C19*3 or *2, which was associated with higher clopidogrel resistance in this group (69.11%, 47/68) than in the control group (64.29%, 36/56). Platelet count (10 9 /L) and hemoglobin (g/L) were the prominent risk factors of clopidogrel resistance. Among the 219 patients, 98 showed dual antiplatelet drug resistance, for which platelet count (10 9 /L) and monocyte count (g/L) were the risk factors. Aspirin resistance was found to usually accompany clopidogrel resistance. |
| first_indexed | 2024-12-11T10:12:59Z |
| format | Article |
| id | doaj.art-1428acea9d2d4607882f100cf122dff6 |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-12-11T10:12:59Z |
| publishDate | 2022-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-1428acea9d2d4607882f100cf122dff62022-12-22T01:11:41ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232022-03-012810.1177/10760296221083674Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCILijie Zhang PhD, MD0Ying Lv PhD, MD1Jianyu Dong PhD, MD2Nana Wang MSc3Zhan Zhan MSc4Yuan Zhao BSc5Shanshan Jiang PhD, MD6 Institute of Hematological Research, , Xi’an, China Institute of Hematological Research, , Xi’an, China Institute of Hematological Research, , Xi’an, China Central laboratory, S, Xi’an, China Inspection Center of Hubei Medical Products Administration (Hubei Center for Vaccine Inspection), Wuhan, China Institute of Hematological Research, , Xi’an, China Institute of Hematological Research, , Xi’an, ChinaSince aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance. The platelet aggregation rate with arachidonic acid (AA, PAg-AA%) and adenosine diphosphate (ADP, PAg-ADP%) of 219 PCI patients were measured after standard treatment for 24 h. The disease history and laboratory data (before PCI) were obtained. We found 101 (46.12%) patients to be aspirin-resistant, and PAg-ADP% was the most prominent risk factor of aspirin resistance. Clopidogrel resistance was present in 157 of 219 patients. Patients in the clopidogrel-resistant group carried more CYP2C19*3 or *2, which was associated with higher clopidogrel resistance in this group (69.11%, 47/68) than in the control group (64.29%, 36/56). Platelet count (10 9 /L) and hemoglobin (g/L) were the prominent risk factors of clopidogrel resistance. Among the 219 patients, 98 showed dual antiplatelet drug resistance, for which platelet count (10 9 /L) and monocyte count (g/L) were the risk factors. Aspirin resistance was found to usually accompany clopidogrel resistance.https://doi.org/10.1177/10760296221083674 |
| spellingShingle | Lijie Zhang PhD, MD Ying Lv PhD, MD Jianyu Dong PhD, MD Nana Wang MSc Zhan Zhan MSc Yuan Zhao BSc Shanshan Jiang PhD, MD Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI Clinical and Applied Thrombosis/Hemostasis |
| title | Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI |
| title_full | Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI |
| title_fullStr | Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI |
| title_full_unstemmed | Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI |
| title_short | Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI |
| title_sort | assessment of risk factors for drug resistance of dual anti platelet therapy after pci |
| url | https://doi.org/10.1177/10760296221083674 |
| work_keys_str_mv | AT lijiezhangphdmd assessmentofriskfactorsfordrugresistanceofdualantiplatelettherapyafterpci AT yinglvphdmd assessmentofriskfactorsfordrugresistanceofdualantiplatelettherapyafterpci AT jianyudongphdmd assessmentofriskfactorsfordrugresistanceofdualantiplatelettherapyafterpci AT nanawangmsc assessmentofriskfactorsfordrugresistanceofdualantiplatelettherapyafterpci AT zhanzhanmsc assessmentofriskfactorsfordrugresistanceofdualantiplatelettherapyafterpci AT yuanzhaobsc assessmentofriskfactorsfordrugresistanceofdualantiplatelettherapyafterpci AT shanshanjiangphdmd assessmentofriskfactorsfordrugresistanceofdualantiplatelettherapyafterpci |